PharmaMar initiates PM060184 Phase I clinical trial in patients with solid tumors

Download PDF Copy

Editorial Checklist

Reviewed

PharmaMarFeb 7 2011

NewsGuard 100/100 Score

PharmaMar SA has announced the commencement of a Phase I clinical trial with PM060184 for patients with solid tumors. PM060184 is a marine-derived, synthetically-produced compound which has shown strong in vitro and in vivo antitumor activity and a favorable safety profile in preclinical toxicology studies. PM060184 is PharmaMar's sixth compound in clinical development.

The trials will be performed in hospitals in the U.S., and also in France and Spain. The primary endpoints of this Phase I trial are to identify the dose limiting toxicity (DLT), the maximum tolerated dose (MTD) and the recommended dose (RD) of PM060184.

Additionally, the drug's pharmacokinetic profile will be defined and a preliminary evaluation of its antitumor activity in patients will be performed.

Source:

Posted in: Drug Trial News | Medical Condition News

Tags: Alzheimer's Disease, Biotechnology, Cancer, Clinical Trial, Compound, Diagnostics, Gene, in vitro, in vivo, Nervous System, Oncology, Preclinical, Toxicology

Comments (0)

Download PDF Copy

Suggested Reading

Matcha green tea enhances cognition and sleep in older adults

Matcha green tea enhances cognition and sleep in older adults

Cognitive behavioral therapy shows promise for prolonged grief disorder

Cognitive behavioral therapy shows promise for prolonged grief disorder

Ozempic effective for patients with chronic kidney damage

Ozempic effective for patients with chronic kidney damage

Weight loss drug semaglutide may offer relief for knee arthritis pain

Weight loss drug semaglutide may offer relief for knee arthritis pain

Cannabidiol shows promise in treating cognitive disorders

Cannabidiol shows promise in treating cognitive disorders

Vitamin K2 reduces the frequency, intensity, and duration of nighttime leg cramps

Vitamin K2 reduces the frequency, intensity, and duration of nighttime leg cramps

HEPA air purifiers fall short in cutting respiratory infections in aged-care facilities

HEPA air purifiers fall short in cutting respiratory infections in aged-care facilities

Higher diet quality associated with reduced risk of prostate cancer grade reclassification

Higher diet quality associated with reduced risk of prostate cancer grade reclassification

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients